Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
November 23, 2022 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Third Quarter 2022 Financial Results and Business Update
November 10, 2022 07:00 ET
|
Humacyte, Inc
-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 – -- Experience with HAV in Ukrainian War Vascular Trauma Mirrors...
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting
November 07, 2022 08:00 ET
|
Humacyte, Inc
Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in...
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
November 03, 2022 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex...
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting
September 23, 2022 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues,...
Humacyte Expands Board of Directors and Leadership Team with New Appointments
September 20, 2022 08:00 ET
|
Humacyte, Inc
Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer DURHAM, N.C., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc....
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress
September 09, 2022 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues,...
Humacyte Presents at Multiple Conferences in September 2022
September 08, 2022 08:01 ET
|
Humacyte, Inc
DURHAM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and...
Humacyte Second Quarter 2022 Financial Results and Business Update
August 12, 2022 07:00 ET
|
Humacyte, Inc
-- Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – -- Hosted key opinion leader (KOL) webinar on HAV in the...
Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022
August 05, 2022 08:00 ET
|
Humacyte, Inc
DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...